Healthcare PE Giant Quadria Capital Finalizes Oversubscribed Fund III at $1.07 Bn

Fund III aims to construct a diversified portfolio of around 10 market-leading companies with minority and majority stakes, complemented by targeted co-investments from Limited Partners (LPs).

Quadria Capital has announced the final close of its third fund, Fund III. The fund secured US$1.07 billion in total commitments, significantly exceeding its initial target of US$800 million. 

The latest fundraising includes US$954 million in primary commitments and US$114 million in committed co-investment capital. 

An additional US$300 million in co-investment capacity is expected during the investment phase, bringing Fund III's total capital under management to approximately US$1.3 billion upon full deployment.

This fund marks a 60% increase over Quadria's previous fund of US$600 million raised in 2020, cementing its position as the largest dedicated healthcare private equity fund in South and Southeast Asia.

Validation Amid Challenging Fundraising Climate

Despite a challenging global fundraising environment, Fund III's oversubscription reflects strong investor confidence in Quadria Capital's strategy. 

"The close of Fund III, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission," said Abrar Mir, Co-Founder and Managing Partner at Quadria Capital. 

"It reflects deep global investor conviction in the transformational opportunity in Asian healthcare, where social impact and financial performance go hand in hand."

Strong Global Institutional Backing

Quadria Capital attracted robust support from a global base of institutional investors. 

Existing investors include sovereign wealth funds, asset managers, and strategic corporates from North America and Europe, as well as new commitments from institutions across the Gulf Cooperation Council (GCC), including Saudi Arabia, the UAE, and Bahrain. 

The fund also saw growing interest from India, with participation from leading banks, insurance firms, and family offices.

The strong presence of impact investors among returning LPs highlights Quadria's continued focus on high-impact, scalable healthcare businesses that cater to underserved populations across Asia.

Tapping into Asia's $5 Trillion Healthcare Market

Quadria Capital is strategically positioned to lead private capital-driven healthcare transformation across Asia's US$5 trillion healthcare sector, which is expected to account for 40% of global healthcare growth by 2030.

"Asia's healthcare sector is at a pivotal moment," noted Dr Amit Varma, Co-Founder and Managing Partner at Quadria. 

"India, in particular, is witnessing rising investment interest in areas such as single-specialty hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing, including APIs and CDMOs. The sector is being driven by increased healthcare consumption, cost-efficiency measures, and deeper integration of technology."

Fund III aims to construct a diversified portfolio of around 10 market-leading companies with minority and majority stakes, complemented by targeted co-investments from Limited Partners (LPs).

Already nearly 40% deployed, the fund has invested in:

Aragen Life Sciences, a global CRDMO serving over 400 pharma clients,

NephroPlus, Asia's largest dialysis network,

Maxivision, a leading Indian eye care chain.

Quadria has also signed two additional investments in Southeast Asia, further extending its regional reach. 

Fund III builds on the firm's successful track record from Funds I and II, reinforcing Quadria's operational expertise and ability to deliver consistent returns to investors.

Stay tuned for more such updates on Digital Health News.

Stay tuned for more such updates on Digital Health News